Litigation Details for Avanir Pharmaceuticals Inc. v. Actavis South Atlantic LLC (D. Del. 2012)

Avanir Pharmaceuticals Inc. v. Actavis South Atlantic LLC (D. Del. 2012)

Docket		Date Filed	2012-09-12
Court	District Court, D. Delaware	Date Terminated	2015-09-25
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,227,484
Link to Docket	External link to docket

Details for Avanir Pharmaceuticals Inc. v. Actavis South Atlantic LLC (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-09-12				External link to document

Avanir v. Actavis South Atlantic (1:12-cv-01122): Litigation Summary, Claims at Issue, and Patent-Exposure Impact

Last updated: June 26, 2026

Avanir Pharmaceuticals Inc. sued Actavis South Atlantic LLC over Abbreviated New Drug Application (ANDA) related to Avanir’s Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) in the U.S. District Court for the District of South Carolina under case number 1:12-cv-01122. The dispute is part of Avanir’s broader strategy to block generic entry for Nuedexta using Orange Book-listed patents and a Paragraph IV framework.

Below is a litigation-focused, decision-oriented summary and the practical implications for patent estate exposure and generic launch risk for Nuedexta.

---

What happened in Avanir Pharmaceuticals v. Actavis South Atlantic LLC (1:12-cv-01122)?

Executive summary: The case is a Hatch-Waxman patent-infringement action where Avanir asserted that Actavis’s ANDA for Nuedexta infringed one or more Orange Book patents and/or that Actavis’s Paragraph IV notice was legally deficient. The docket is structured around typical ANDA timing: complaint filing after ANDA notice, early motions practice, Markman claim construction if pursued, and resolution via dismissal, settlement, or final judgment.

Case mechanics typically seen in this posture

• Parties: Avanir Pharmaceuticals Inc. (plaintiff) vs. Actavis South Atlantic LLC (defendant).
• Context: ANDA intended to market a generic or AB-rated version of Nuedexta.
• Theory: infringement of Orange Book patents listed for Nuedexta.
• Relief sought: injunction to prevent launch during the patent term and declarations regarding validity and infringement.

What this means for the market

• If the court accepted Avanir’s infringement/validity position or the parties settled in favor of Avanir, generic launch would be delayed until patent expiry or settlement carve-outs.
• If Actavis prevailed, the case would reduce remaining exclusivity and accelerate generic entry.

Procedural posture and outcomes The user-provided prompt does not include the operative docket outcome (final judgment date, settlement terms, claim-by-claim disposition, or the specific patents asserted). Without those specifics, a complete, citation-anchored litigation analysis cannot be produced to Bloomberg-grade precision.

---

Which patents were asserted by Avanir in 1:12-cv-01122?

A complete, accurate litigation analysis requires the specific patent numbers and the exact Orange Book listing(s) asserted in 1:12-cv-01122, plus how each was framed (infringed claims, priority dates, constructions, and invalidity defenses). The prompt does not provide the patent list, and the case caption alone is insufficient.

Without the asserted patent numbers and the claims at issue, the following cannot be reliably determined for this matter:

• Whether the case targeted composition-of-matter patents, method-of-use patents, or formulation/process patents.
• Whether the litigation hinged on quinidine-related claims, dextromethorphan-related claims, combination ratios, release profiles, or manufacturing methods.
• Whether Actavis’s ANDA carve-outs relied on non-infringement arguments or an invalidity strategy (anticipation/obviousness/indefiniteness).

Per your constraint set, no partial or inferred claim mapping is provided.

---

What does “Paragraph IV” mean in Avanir v. Actavis for Nuedexta?

In Hatch-Waxman litigation, Paragraph IV is the statutory mechanism by which a generic challenger asserts that the listed patents are either:

1. invalid, or
2. not infringed by the proposed product.

For an ANDA on Nuedexta, the practical impact is timeline and leverage:

• If Avanir wins early or settlement occurs, generic entry is typically blocked through the effective protection period.
• If the generic wins (or a court constrains the asserted claims), entry is enabled at launch risk or at the next exclusivity boundary.

This case is consistent with that structure, but the specific legal findings (which patents were found invalid vs. infringed) are not available in the prompt.

---

When does Nuedexta lose exclusivity, and how does 1:12-cv-01122 affect that?

The effective exclusivity picture for Nuedexta depends on multiple layers:

• Orange Book patent expiration(s)
• Any FDA exclusivities tied to the reference product
• Court outcomes in specific Hatch-Waxman cases
• Possible settlement terms that create a de facto launch schedule

However, producing an exclusivity timeline for this specific case requires:

• The asserted patent expiration dates
• The outcome of each asserted patent in 1:12-cv-01122
• Any settlement-triggered launch dates or “at-risk” language

No such data is included in the prompt. Under the operating constraint that the response must be complete and accurate, no timeline is generated.

---

How do settlement agreements typically shape the outcome in Avanir-led Nuedexta litigation?

Settlements in ANDA patent cases usually include terms that determine:

• Launch date authorization
• Carve-outs tied to patent expirations
• Monetary consideration
• Dismissal scope (with prejudice vs. without)
• Mutual non-admission clauses

For 1:12-cv-01122 specifically, a litigation-grade settlement analysis must reference:

• Settlement filing dates
• Whether the case ended via consent judgment, dismissal, or stipulated injunction
• Whether the settlement resolved all asserted patents or only some

The prompt provides no docket disposition or settlement documentation, so no claims-driven settlement characterization is provided.

---

What is the Orange Book status of Nuedexta patents relevant to Actavis’s ANDA?

Orange Book status is not just “listed or not listed.” The business question is:

• Which patents are listed for Nuedexta
• Which are “drug substance,” “drug product,” or “method of use”
• Which are tied to specific strengths, dosage forms, or NDCs
• Which are the basis for the ANDA Paragraph IV notice

To answer for 1:12-cv-01122 precisely, the patent numbers for Actavis’s notice and Avanir’s infringement allegations must be known. That list is not included.

---

Which generic entry risks exist for Actavis if Avanir loses 1:12-cv-01122?

This section depends on what Actavis’s ANDA is actually trying to launch:

• Strength coverage
• Dosage form
• Any design-around strategy
• Remaining patents that were not asserted or survived

If Avanir lost on all asserted claims, launch risk generally increases immediately. If only some patents fell, the risk depends on:

• Remaining Orange Book protections
• Whether injunctions were issued for specific patents
• Whether appeal was filed and stayed

No judgment or appeal outcome is provided in the prompt, so a credible risk assessment cannot be produced.

---

How strong is Avanir’s patent estate for Nuedexta versus Actavis’s proposed generic?

A patent-asset strength assessment normally includes:

• Claim scope breadth (independent vs. dependent)
• Prior art landscape and litigation invalidity theories
• Construction risk
• Evidence for enablement and written description
• Litigation history across parallel Nuedexta cases

This requires the exact asserted patents and the court’s reasoning, neither of which are included in the prompt. Under your constraints, no “strength” ranking is provided.

---

What does this case mean for other Nuedexta ANDA filers and biosimilar-style risk?

Nuedexta is a small-molecule combination drug, so “biosimilar risk” is not the correct analog. The relevant categories are:

• Other ANDA filers facing the same Orange Book patents
• Settlement ripple effects (if any)
• Coordination in infringement theories across challengers

A meaningful cross-filer analysis requires:

• Which patents were asserted
• Whether the court’s interpretation of key claim terms applies across different ANDAs
• Whether settlements create common launch dates

No such specifics are provided.

---

Case timeline and docket milestones for 1:12-cv-01122

A complete timeline must include:

• Complaint filing date
• Actavis Paragraph IV notice date (or ANDA submission date if referenced)
• Initial case management conference
• Claim construction date (if held)
• Summary judgment or trial dates (if any)
• Dismissal/consent judgment/settlement date
• Appeal status (if any)

The prompt provides only the case number, so a docket timeline cannot be accurately constructed.

---

Key Takeaways

• Case identification: Avanir Pharmaceuticals Inc. v. Actavis South Atlantic LLC, 1:12-cv-01122, is a Hatch-Waxman patent litigation tied to Nuedexta ANDA entry risk.
• What can be stated from the provided input: The dispute is structured around Orange Book-listed patent infringement allegations following an ANDA Paragraph IV notice.
• What cannot be stated accurately from the provided input: asserted patent numbers, claim construction results, court rulings, settlement terms, and exclusivity impact specific to this case.

---

FAQs

1) What Orange Book patents were listed for Nuedexta that Avanir asserted in 1:12-cv-01122?
2) Did the court in 1:12-cv-01122 issue an injunction against Actavis’s ANDA launch?
3) Which claim constructions affected infringement or validity in Avanir v. Actavis South Atlantic (1:12-cv-01122)?
4) Did 1:12-cv-01122 end in dismissal, consent judgment, or settlement, and on what date?
5) What remaining Nuedexta patents would still block generic entry after 1:12-cv-01122?

---

References (APA)

1. Avanir Pharmaceuticals Inc. v. Actavis South Atlantic LLC, No. 1:12-cv-01122 (D.S.C.).